What Is the Right Dose? The Elusive Optimal Biologic Dose in Phase I Clinical Trials

This publication has 5 references indexed in Scilit:

• Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer
  Journal of Clinical Oncology, 2006
• Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity
  Blood, 2005
• Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies
  Journal of Clinical Oncology, 2005
• Clinical Trial Designs for Therapeutic Cancer Vaccines
  Published by Springer Nature ,2005
• Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice
  JNCI Journal of the National Cancer Institute, 2004